SG11202009970VA - Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use - Google Patents
Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of UseInfo
- Publication number
- SG11202009970VA SG11202009970VA SG11202009970VA SG11202009970VA SG11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- beta
- methods
- cross
- latent tgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019155278 | 2019-08-28 | ||
PCT/JP2020/032522 WO2021039945A1 (en) | 2019-08-28 | 2020-08-28 | Cross-species anti-latent tgf-beta 1 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009970VA true SG11202009970VA (en) | 2021-04-29 |
Family
ID=74684250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009970VA SG11202009970VA (en) | 2019-08-28 | 2020-08-28 | Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use |
Country Status (18)
Country | Link |
---|---|
US (2) | US11312767B2 (en) |
EP (1) | EP4021498A4 (en) |
JP (2) | JP6846564B2 (en) |
KR (2) | KR102376605B1 (en) |
CN (1) | CN114729370A (en) |
AR (1) | AR120077A1 (en) |
AU (1) | AU2020340176A1 (en) |
BR (1) | BR112022003412A2 (en) |
CA (1) | CA3149151A1 (en) |
CL (1) | CL2022000438A1 (en) |
CO (1) | CO2022001789A2 (en) |
CR (1) | CR20220125A (en) |
IL (1) | IL290816A (en) |
MX (1) | MX2022001938A (en) |
PE (1) | PE20221447A1 (en) |
SG (1) | SG11202009970VA (en) |
TW (2) | TWI737469B (en) |
WO (1) | WO2021039945A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102376605B1 (en) | 2019-08-28 | 2022-03-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-religious anti-latent TGF-β1 antibody and method of use |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005105144A1 (en) | 2004-04-30 | 2007-09-13 | 協和醗酵工業株式会社 | Latent TGF-β activation inhibitor |
WO2011102483A1 (en) | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | HUMAN LAP TGF-β BINDING ANTIBODY |
WO2013134365A1 (en) | 2012-03-08 | 2013-09-12 | Ludwig Institute For Cancer Research Ltd | TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP3139957A4 (en) | 2014-05-06 | 2018-04-25 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP3244926A4 (en) | 2015-01-14 | 2018-06-27 | The Brigham and Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
CN113896789A (en) * | 2015-09-15 | 2022-01-07 | 供石公司 | Anti-pro/latent myostatin antibodies and uses thereof |
EP4169942A1 (en) | 2016-03-11 | 2023-04-26 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
WO2018043734A1 (en) * | 2016-09-05 | 2018-03-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-tgf-beta 1 antibodies and methods of use |
PE20191661A1 (en) | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | INHIBITORS OF TGF BETA1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME |
GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
JP2020186172A (en) | 2017-06-19 | 2020-11-19 | 株式会社ボナック | ANTI-TGF-β1 ANTIBODIES |
CA3071427A1 (en) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
WO2019045086A1 (en) * | 2017-08-29 | 2019-03-07 | 林化成株式会社 | USE FOR SPECIFIC ANTIBODY FOR ACTIVE OR LATENT TGF-β1 |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
JP7315566B2 (en) * | 2018-02-23 | 2023-07-26 | 中外製薬株式会社 | Cross-species anti-latent TGF-β1 antibodies and methods of use |
TW202019957A (en) | 2018-07-11 | 2020-06-01 | 美商供石公司 | Tgfβ1 inhibitors and use thereof |
TW202005981A (en) | 2018-07-11 | 2020-02-01 | 美商供石公司 | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF |
MX2021009175A (en) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFß AND USES THEREOF. |
KR102376605B1 (en) | 2019-08-28 | 2022-03-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-religious anti-latent TGF-β1 antibody and method of use |
WO2022180764A1 (en) * | 2021-02-26 | 2022-09-01 | Chugai Seiyaku Kabushiki Kaisha | Uses of cross-species anti-latent tgf-beta 1 antibodies |
-
2020
- 2020-08-28 KR KR1020207034432A patent/KR102376605B1/en active IP Right Grant
- 2020-08-28 PE PE2022000303A patent/PE20221447A1/en unknown
- 2020-08-28 BR BR112022003412A patent/BR112022003412A2/en unknown
- 2020-08-28 EP EP20858423.5A patent/EP4021498A4/en active Pending
- 2020-08-28 TW TW109129510A patent/TWI737469B/en active
- 2020-08-28 JP JP2020144024A patent/JP6846564B2/en active Active
- 2020-08-28 CA CA3149151A patent/CA3149151A1/en active Pending
- 2020-08-28 CN CN202080061243.XA patent/CN114729370A/en active Pending
- 2020-08-28 KR KR1020227008695A patent/KR20220043930A/en not_active Application Discontinuation
- 2020-08-28 TW TW110128876A patent/TW202142571A/en unknown
- 2020-08-28 MX MX2022001938A patent/MX2022001938A/en unknown
- 2020-08-28 SG SG11202009970VA patent/SG11202009970VA/en unknown
- 2020-08-28 WO PCT/JP2020/032522 patent/WO2021039945A1/en unknown
- 2020-08-28 CR CR20220125A patent/CR20220125A/en unknown
- 2020-08-28 AU AU2020340176A patent/AU2020340176A1/en active Pending
- 2020-08-28 AR ARP200102422A patent/AR120077A1/en unknown
-
2021
- 2021-03-01 JP JP2021031586A patent/JP2021118685A/en active Pending
- 2021-09-03 US US17/466,509 patent/US11312767B2/en active Active
-
2022
- 2022-02-21 CO CONC2022/0001789A patent/CO2022001789A2/en unknown
- 2022-02-22 IL IL290816A patent/IL290816A/en unknown
- 2022-02-23 CL CL2022000438A patent/CL2022000438A1/en unknown
- 2022-03-16 US US17/696,269 patent/US20220204605A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021039945A1 (en) | 2021-03-04 |
US20210395356A1 (en) | 2021-12-23 |
US11312767B2 (en) | 2022-04-26 |
TW202142571A (en) | 2021-11-16 |
CN114729370A (en) | 2022-07-08 |
EP4021498A1 (en) | 2022-07-06 |
KR102376605B1 (en) | 2022-03-21 |
AR120077A1 (en) | 2022-02-02 |
TW202122422A (en) | 2021-06-16 |
MX2022001938A (en) | 2022-03-11 |
TWI737469B (en) | 2021-08-21 |
PE20221447A1 (en) | 2022-09-21 |
AU2020340176A1 (en) | 2022-04-14 |
JP6846564B2 (en) | 2021-03-24 |
KR20210039328A (en) | 2021-04-09 |
US20220204605A1 (en) | 2022-06-30 |
KR20220043930A (en) | 2022-04-05 |
JP2021036864A (en) | 2021-03-11 |
IL290816A (en) | 2022-04-01 |
CA3149151A1 (en) | 2021-03-04 |
BR112022003412A2 (en) | 2022-05-24 |
JP2021118685A (en) | 2021-08-12 |
CL2022000438A1 (en) | 2022-11-25 |
EP4021498A4 (en) | 2024-01-03 |
CR20220125A (en) | 2022-05-04 |
CO2022001789A2 (en) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
SG11202108398YA (en) | Anti-claudin 18 antibodies and methods of use thereof | |
EP3852805A4 (en) | Anti-lilrb2 antibodies and methods of use thereof | |
IL290816A (en) | Cross-species anti-latent tgf-beta 1 antibodies and methods of use | |
IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
IL289829A (en) | Immunomodulatory antibodies and methods of use thereof | |
EP3755723A4 (en) | Cross-species anti-latent tgf-beta 1 antibodies and methods of use | |
IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
IL287282A (en) | Anti-mertk antibodies and their methods of use | |
SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
IL289952A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
IL277212A (en) | Anti-klk5 antibodies and methods of use | |
EP3731867A4 (en) | Anti-lrp5/6 antibodies and methods of use | |
IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
IL291730A (en) | Protein-macromolecule conjugates and methods of use thereof | |
EP3746484A4 (en) | Anti-ms4a6a antibodies and methods of use thereof | |
EP4061848A4 (en) | Anti-ror-2 antibodies and methods of use | |
IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
SG11202113221RA (en) | Anti-cd137l antibodies and methods of using same |